Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:IMA NASDAQ:TCRT NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$4.39+0.9%$5.26$4.14▼$15.99$12.59M1.5954,916 shs16,014 shsIMAImageneBio$5.49+0.7%$5.54$3.94▼$18.00$58.49M0.72224,132 shs839 shsTCRTAlaunos Therapeutics$2.74-0.4%$2.77$1.67▼$6.20$66.92M-1.0717,990 shs2,420 shsTILInstil Bio$8.13+0.2%$8.22$5.67▼$42.79$55.12M1.9180,534 shs6,464 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics-7.45%-16.18%-31.50%-47.59%-67.87%IMAImageneBio-0.37%-6.36%-3.71%-11.38%-64.52%TCRTAlaunos Therapeutics-2.61%+14.08%+7.09%-16.82%+3.52%TILInstil Bio0.00%-0.12%+2.66%-7.42%-72.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$4.39+0.9%$5.26$4.14▼$15.99$12.59M1.5954,916 shs16,014 shsIMAImageneBio$5.49+0.7%$5.54$3.94▼$18.00$58.49M0.72224,132 shs839 shsTCRTAlaunos Therapeutics$2.74-0.4%$2.77$1.67▼$6.20$66.92M-1.0717,990 shs2,420 shsTILInstil Bio$8.13+0.2%$8.22$5.67▼$42.79$55.12M1.9180,534 shs6,464 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics-7.45%-16.18%-31.50%-47.59%-67.87%IMAImageneBio-0.37%-6.36%-3.71%-11.38%-64.52%TCRTAlaunos Therapeutics-2.61%+14.08%+7.09%-16.82%+3.52%TILInstil Bio0.00%-0.12%+2.66%-7.42%-72.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$13.00196.13% UpsideIMAImageneBio 2.00Hold$26.50382.70% UpsideTCRTAlaunos Therapeutics 1.00SellN/AN/ATILInstil Bio 1.67Reduce$66.00711.81% UpsideCurrent Analyst Ratings BreakdownLatest CVKD, IMA, TCRT, and TIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026IMAImageneBio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform4/29/2026TCRTAlaunos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.003/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AIMAImageneBioN/AN/AN/AN/A$11.91 per shareN/ATCRTAlaunos Therapeutics$3K22,305.43N/AN/A$0.93 per share2.95TILInstil BioN/AN/AN/AN/A$16.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)IMAImageneBio-$45.35M-$5.79N/AN/AN/AN/A-38.96%-34.60%N/ATCRTAlaunos Therapeutics-$4.18M-$2.13N/AN/AN/AN/A-165.94%-123.50%8/18/2026 (Estimated)TILInstil Bio-$71.37M-$7.08N/AN/AN/AN/A-39.76%-22.38%8/12/2026 (Estimated)Latest CVKD, IMA, TCRT, and TIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026TCRTAlaunos TherapeuticsN/A-$0.59N/A-$0.59N/AN/A5/15/2026Q1 2026TILInstil Bio-$0.62-$0.62N/A-$0.62N/AN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A5/7/2026Q1 2026IMAImageneBio-$0.70-$0.95-$0.25-$0.95N/AN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/31/2026Q4 2025TCRTAlaunos TherapeuticsN/A-$0.36N/A-$0.36N/A$0.00 million3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/A3/10/2026Q4 2025IMAImageneBioN/A$0.34N/A$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A2.682.68IMAImageneBioN/A18.3918.39TCRTAlaunos TherapeuticsN/A1.631.63TILInstil Bio0.7739.8739.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%IMAImageneBio75.00%TCRTAlaunos Therapeutics27.72%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%IMAImageneBio5.94%TCRTAlaunos Therapeutics16.14%TILInstil Bio47.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableIMAImageneBio7010.65 million10.02 millionNot OptionableTCRTAlaunos Therapeutics4024.42 million20.48 millionNo DataTILInstil Bio4106.78 million3.59 millionNo DataCVKD, IMA, TCRT, and TIL HeadlinesRecent News About These CompaniesInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 29, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,January 27, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 22, 2026 | prnewswire.comTIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyJanuary 20, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 20, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 15, 2026 | prnewswire.comInstil Bio (TIL) Price Target Decreased by 45.17% to 53.55January 14, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 8, 2026 | prnewswire.comHC Wainwright & Co. downgrades Instil Bio (TIL)January 8, 2026 | msn.comArrowhead showcases early obesity data; Instil bails on PD-1/VEGF drugJanuary 7, 2026 | biopharmadive.comBInstil Bio shares slide on discontinuation of lead clinical programsJanuary 6, 2026 | proactiveinvestors.comInstil Bio Pulls Plug On Lead Drug DevelopmentJanuary 6, 2026 | benzinga.comInstil Bio stock falls after subsidiary discontinues AXN-2510 developmentJanuary 6, 2026 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX IPO: Opportunity? Or the Ultimate Hype Trade?By Chris Markoch | May 22, 2026Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceBy Ryan Hasson | May 8, 20263 Industrial Stocks That Just Crushed EarningsBy Dan Schmidt | May 13, 2026Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageBy Jeffrey Neal Johnson | May 6, 2026YETI Rallies After Earnings Beat and Raised OutlookBy Jennifer Ryan Woods | May 14, 2026CVKD, IMA, TCRT, and TIL Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$4.39 +0.04 (+0.92%) As of 12:49 PM EasternCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.ImageneBio NASDAQ:IMA$5.49 +0.04 (+0.73%) As of 11:39 AM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Alaunos Therapeutics NASDAQ:TCRT$2.74 -0.01 (-0.36%) As of 12:53 PM EasternAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Instil Bio NASDAQ:TIL$8.13 +0.02 (+0.25%) As of 12:38 PM EasternInstil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Build 2026 Is Really Just One Big AI Stress Test Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod MongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today" Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
